• Happy New Year
    Happy New Year

    Happy CACA 10 year Anniversary

  • Pittcon 2009
    Pittcon 2009

    Pittcon 2009, Chicago, March 2009

  • HPLC 2010
    HPLC 2010

    HPLC 2010, Boston, June 2010

  • Pittcon 2011
    Pittcon 2011

    Pittcon 2011, Atlanta, March 2011

  • Pittcon 2012
    Pittcon 2012

    Pittcon 2012, Orlando, March 2012

  • HPLC 2012
    HPLC 2012

    HPLC 2012, Anaheim, June 2012

  • Pittcon 2014
    Pittcon 2014

    Pittcon 2014, Chicago, March 2014

Please register for

Understanding and Overcoming Separation Challenges in the Biological Drug Development Process

Nov 13, 2019 12:00 PM EST at: 

https://attendee.gotowebinar.com/register/1243579938895030786

Andrew HarronAndrew Harron, Ph.D 
Applications Research Scientist 
Advanced Materials Technology

 

The landscape for new biological drug development continues to evolve in complexity. With biosimilars entering the market and originator products coming off patent, the competitive race for market dominance is reliant on:

  1. A deeper understanding of the drug product to produce a more comprehensive drug filing in order to delay or prevent market entrance by a competitor.
  2. A more thorough characterization of an innovator product or proposed biosimilar in order to take full advantage of the Regulatory pathways to rapid approval

Pharmaceutical companies employ many orthogonal techniques and methodologies to better develop a complete picture of biopharmaceuticals which are inherently more complex than small molecules. The use of various separation technologies in the analysis of biological drugs is pervasive in the overall new product development. While not all separations involve HPLC, most do and would benefit from the unique characteristics of superficially porous particle columns. This webinar will walk through the biological drug development process, while focusing on the unique separation needs of biologicals, including a conversation on intact and reduced mAb mass analysis by LC/MS. The webinar will also demonstrate a way to develop an understanding of the protein backbone via peptide mapping and glycosylation while emphasizing areas in the workflow where superficially porous particle columns with appropriate pore sizes offer a unique advantage.

 

Key Learning Objectives:

  • Why is it important to fully characterize a new or biosimilar product?
  • What is required to fully characterize a biopharmaceutical product?
  • How to enable the characterization of a biopharmaceutical product through better chromatography?

 

Who Should Attend:

  • Separation scientists involved in developing LC and LC/MS characterization methods of biopharmaceutical products and those interested in learning more about separation.

 

After registering, you will receive a confirmation email containing information about joining the webinar.